Myriad Genetics, Inc.
MYGN
$10.18
-$0.34-3.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 210.60M | 213.30M | 211.50M | 202.20M | 196.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 210.60M | 213.30M | 211.50M | 202.20M | 196.60M |
| Cost of Revenue | 59.70M | 63.50M | 64.40M | 64.60M | 61.60M |
| Gross Profit | 150.90M | 149.80M | 147.10M | 137.60M | 135.00M |
| SG&A Expenses | 136.00M | 139.10M | 144.90M | 140.60M | 144.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 227.90M | 231.10M | 236.40M | 230.10M | 227.00M |
| Operating Income | -17.30M | -17.80M | -24.90M | -27.90M | -30.40M |
| Income Before Tax | -39.10M | -21.20M | -37.20M | -25.90M | -32.30M |
| Income Tax Expenses | 3.40M | 900.00K | -500.00K | 100.00K | -1.10M |
| Earnings from Continuing Operations | -42.50M | -22.10M | -36.70M | -26.00M | -31.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.50M | -22.10M | -36.70M | -26.00M | -31.20M |
| EBIT | -17.30M | -17.80M | -24.90M | -27.90M | -30.40M |
| EBITDA | -2.50M | -2.20M | -9.80M | -12.20M | -15.30M |
| EPS Basic | -0.47 | -0.24 | -0.41 | -0.29 | -0.36 |
| Normalized Basic EPS | -0.12 | -0.13 | -0.18 | -0.18 | -0.23 |
| EPS Diluted | -0.47 | -0.24 | -0.41 | -0.29 | -0.37 |
| Normalized Diluted EPS | -0.12 | -0.13 | -0.18 | -0.18 | -0.23 |
| Average Basic Shares Outstanding | 91.10M | 90.90M | 90.60M | 89.90M | 86.10M |
| Average Diluted Shares Outstanding | 91.10M | 90.90M | 90.60M | 89.90M | 86.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
